356 active not recruiting. 356 Phase 1, 131 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 356 | Active not recruiting 356 |
| Phase 2 | 131 | Active not recruiting 131 |
Follow Lymphoproliferative Disorders: new trials by email Literature Review of Lymphoproliferative Disorders trials Research Report on Lymphoproliferative Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study to Evaluate the Effects of RO7875913 in Healthy Participants and of RO7875913 With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma RO7875913, Placebo, Cevostamab - Healthy Volunteers, Relapsed Multiple Myeloma | Phase 1 | Active not recruiting | Genentech, Inc. | 240 | 2026-03-11 | 2026-09-30 |
| Study of BMS-986453 in Newly Diagnosed Multiple Myeloma BMS-986453 - Multiple Myeloma | Phase 1 | Active not recruiting | Susan Bal | 25 | 2026-02-09 | 2026-10-09 |
| A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia Blinatumomab, Mini-CVD, MTX/ARA-C - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 3 | 2026-01-30 | 2026-08-18 |
| Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia Autologous Anti-CD19/CD20/CD22 CAR T-cells, Biospecimen Collection, Bone Marrow Aspiration - Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | Ohio State University Comprehensive Cancer Center | 24 | 2026-01-14 | 2026-08-26 |
| A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia Blinatumomab - Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Amgen | 104 | 2025-12-08 | 2026-10-05 |
| Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Zanubrutinib, Rituximab, Obinutuzumab - Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Phase 1 | Active not recruiting | University of Utah | 24 | 2025-09-12 | 2026-06-30 |
| Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome epcoritamab - Leukemia, Chronic Lymphocytic, Richter Syndrome | Phase 1 | Active not recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 5 | 2025-07-18 | 2026-11-09 |
| A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma Cevostamab, Tocilizumab - Multiple Myeloma | Phase 1 | Active not recruiting | Hoffmann-La Roche | 20 | 2025-05-13 | 2026-08-28 |
| A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Glofitamab, Tocilizumab, Obinutuzumab - Lymphoma | Phase 1 | Active not recruiting | Hoffmann-La Roche | 50 | 2025-04-28 | 2026-10-06 |
| Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant Recombinant glycosylated human interleukin-7, Melphalan, Autologous hematopoietic cell transplant - Multiple Myeloma | Phase 1 | Active not recruiting | Washington University School of Medicine | 30 | 2025-04-04 | 2026-09-01 |
| A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer Cobolimab, Dostarlimab - Melanoma, Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | GlaxoSmithKline | 83 | 2025-03-06 | 2025-11-12 |
| A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Obinutuzumab, ABBV-453 - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 | Active not recruiting | AbbVie | 4 | 2025-01-27 | 2026-09-11 |
| Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma ABBV-291 - Non-Hodgkin's Lymphoma | Phase 1 | Active not recruiting | AbbVie | 21 | 2025-01-16 | 2026-09-29 |
| A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma JNJ-87562761 - Relapsed or Refractory Multiple Myeloma | Phase 1 | Active not recruiting | Janssen Research & Development, LLC | 17 | 2024-12-19 | 2026-11-03 |
| A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma TLN-254 - Lymphoma | Phase 1 | Active not recruiting | Treeline Biosciences, Inc. | 50 | 2024-12-16 | 2026-08-18 |
| A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL) JNJ-80948543, JNJ-75348780 - Lymphoma, Non-Hodgkin | Phase 1 | Active not recruiting | Janssen Research & Development, LLC | 19 | 2024-10-22 | 2026-11-03 |
| A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment INT2104 - Lymphomas Non-Hodgkin's B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma | Phase 1 | Active not recruiting | Kite, A Gilead Company | 10 | 2024-09-20 | 2026-09-08 |
| A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma CLN-619 - Multiple Myeloma | Phase 1 | Active not recruiting | Cullinan Therapeutics Inc. | 30 | 2024-09-03 | 2025-09-18 |
| A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies Ossium HPC Marrow, Bone Marrow Transplant, Pre-transplant conditioning - Myeloablative (MAC), Pre-transplant conditioning - Reduced Intensity (RIC) - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Ossium Health, Inc. | 12 | 2024-08-16 | 2026-09-10 |
| Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma Subcutaneous (SC) Etentamig, Intravenous (IV) Etentamig - Multiple Myeloma | Phase 1 | Active not recruiting | AbbVie | 60 | 2024-06-17 | 2026-03-27 |
Showing 20 of 356. Sign in to see all of them.
Multiple Myeloma (79) · Lymphoma, Non-Hodgkin (73) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (54) · Lymphoma, Large B-Cell, Diffuse (53) · Leukemia, Lymphocytic, Chronic, B-Cell (52) · Lymphoma, Follicular (49) · Lymphoma (46) · Lymphoma, B-Cell (43) · Recurrence (42) · Lymphoma, Mantle-Cell (33) · Burkitt Lymphoma (27) · Leukemia (27) · Lymphoma, B-Cell, Marginal Zone (22) · Leukemia, Myeloid, Acute (20) · Hodgkin Disease (19)
Hemic and Lymphatic Diseases (352) · Immune System Diseases (348) · Immunoproliferative Disorders (348) · Neoplasms by Histologic Type (348) · Neoplasms (335) · Lymphatic Diseases (277) · Hematologic Diseases (207) · Lymphoma (173) · Leukemia, Lymphoid (115) · Lymphoma, Non-Hodgkin (112) · Pathological Conditions, Signs and Symptoms (108) · Pathologic Processes (107) · Leukemia (106) · Disease Attributes (100)
Cyclophosphamide (57) · Rituximab (40) · Dexamethasone (37) · Lenalidomide (36) · fludarabine (30) · fludarabine phosphate (26) · venetoclax (23) · Calcium Dobesilate (18) · Specimen Handling (18) · Vincristine (18) · Doxorubicin (17) · Biopsy (16) · Prednisone (16) · ibrutinib (16) · obinutuzumab (16)
Memorial Sloan Kettering Cancer Center (24) · National Cancer Institute (NCI) (20) · City of Hope Medical Center (18) · Baylor College of Medicine (14) · Janssen Research & Development, LLC (12) · AbbVie (11) · Dana-Farber Cancer Institute (11) · GlaxoSmithKline (9) · Hoffmann-La Roche (8) · Acerta Pharma BV (6) · Genmab (6) · M.D. Anderson Cancer Center (6) · Seattle Children's Hospital (6) · UNC Lineberger Comprehensive Cancer Center (6) · Mayo Clinic (5)
United States (296) · Spain (50) · Australia (47) · France (41) · Canada (39) · Italy (37) · China (32) · United Kingdom (30) · Germany (25) · Israel (25) · South Korea (25) · Japan (24) · Belgium (19) · Poland (18) · Denmark (13)
Jae Park, MD (6) · Colleen Annesley, MD (5) · Helen E Heslop, MD (5) · Alex F Herrera (3) · Carlos Ramos, MD (3) · Helen Heslop, MD (3) · Natalie Grover, MD (3) · Alexey Danilov (2)
PMID 34515338, PMID 41429239, PMID 41671463, PMID 27118452, PMID 34889384, PMID 39319495, PMID 40226119, PMID 40233328, PMID 40246579, PMID 41052404, PMID 41742895, PMID 42341322, PMID 42411504, PMID 42541678, PMID 20385792, PMID 21849486, PMID 22047558, PMID 22225488, PMID 22285199, PMID 23417027, PMID 24030379, PMID 24753538, PMID 24782509, PMID 25355819, PMID 25734008, PMID 25824111, PMID 25977584, PMID 26072403, PMID 26639404, PMID 26641137, PMID 26907630, PMID 27270177, PMID 28408462, PMID 28714866, PMID 29315015, PMID 29385376, PMID 29388903, PMID 29481659, PMID 30091600, PMID 30111609, PMID 30692121, PMID 30860496, PMID 30901302, PMID 30938714, PMID 31088809, PMID 31262783, PMID 31650176, PMID 31876911, PMID 32084260, PMID 32122924
2023 (36), 2019 (11), P30CA033572 (9), 2016 (4), P50CA107399 (3), 2015 (2), 2018 (2), K24CA201524 (2), P30CA138292 (2), P50CA126752 (2), UM1CA186644 (2), UM1CA186686 (2), UM1CA186689 (2), UM1CA186712 (2), UM1CA186717 (2)